Skip to content

Palvella Therapeutics PVLA Change in Lease Liabilities

Change in Lease Liabilities at other companies

Precigen logo
PrecigenPGEN
-$75K+21.1%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$3.19M-17.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$1.85M-26.0%
Arrowhead Research logo
Arrowhead ResearchARWR
-$1.21M-7.5%
Roivant Sciences logo
Roivant SciencesROIV
-$275K-14.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$139K-7.8%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's change in lease liabilities?
Palvella Therapeutics (PVLA) reported change in lease liabilities of -$49K in Q1 2026.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.